Anti-TNF- treatment may play its role by suppressing uc.261 expression in colitis mice. Crohns disease Supplemental_Digital_Content_2.pdf (147K) GUID:?AD6057D3-3514-45F0-A996-A616EF2E216D Supplemental material, Supplemental_Digital_Content_2 for Transcribed ultraconserved region (T-UCR) uc.261 expression is closely correlated with disease activity and intestinal permeability in Crohns disease by Xiao-Xian Qian, Chen-Wen Cai, Han-Yang Li, Li-Jie Lai, Dong-Juan Song, Yu-Qi Qiao, Jun Shen and Zhi-Hua Ran in Therapeutic Advances in Gastroenterology Abstract Objectives: Transcribed ultraconserved region (T-UCR) uc.261 is reported to participate in intestinal mucosa barrier damage in Crohns disease (CD). The aim of this study was to determine the association with disease activity and intestinal permeability. Methods: Uc.261 HA130 level in colon mucosa and Harvey-Bradshaw Index (HBI) were evaluated in 20 active CD patients. Uc.261 expression and transepithelial electrical resistance (TEER) were determined in Caco2 and T84 cells treated with tumor necrosis factor alpha (TNF-), respectively. Body weight, disease activity index (DAI), colon length, histological index (HI), intestinal permeability to FITC-dextran, uc.261, and tight junction proteins (TJPs) levels were evaluated in BALB/C mice treated with saline enema, trinitrobenzene sulfonic acid HA130 (TNBS)/ethanol enema, and anti-TNF- monoclonal antibody injection, respectively. Results: Uc.261 expression was overexpressed in CD patients, TNF- treated cells, and colitis mice. Uc.261 HA130 expression was positively correlated with HBI (and em Rabbit Polyclonal to Akt (phospho-Ser473) in vitro /em . TNBS-induced colitis mice is often used to simulate pathological changes in human CD. In other studies,28 changes in several parameters have often been investigated in TNBS-induced colitis mice, including body weight, DAI, length of colon, HI of colon, intestinal permeability to FITC-Dextran, and TJP mRNA/protein expression. Body weight, DAI, length of colon, and HI of colon can reflect disease activity. Intestinal permeability to FITC-Dextran is a direct measurement to study colonic permeability.20 TJPs are important components of the mucosal barrier. Impaired mucosal barrier has lower expression of TJPs. The results of our study were similar to those previous studies. TNBS-induced colitis mice showed decreased body weight, length of colon, and TJP mRNA/protein expression, while their DAI, HI of colon, and intestinal permeability to FITC-Dextran greatly increased.21 In addition, we studied the expression of uc.261 in colon mucosa and found that TNBS-induced colitis mice overexpressed uc.261. Furthermore, we studied the association of uc.261 expression with other parameters, and found that uc.261 had a negative correlation with body weight, length of colon, and TJP mRNA/protein expression, and a positive correlation with DAI, HI, and intestinal permeability to FITC-Dextran. These findings indicated that uc.261 was closely associated with disease activity and intestinal permeability in TNBS-induced colitis mice. Combined with our previous findings in Caco2 and T84 cells,3 we suggested that overexpressed uc.261 may participate in some signal pathways associated with inflammatory reactions and damage to epithelial integrity in colitis mice. Pro-inflammatory cytokines play roles in the pathogenesis of human CD and TNBS-induced colitis mice. TNF, IFN-, and IL-18 mRNAs in colon mucosa were unregulated in TNBS colitis, and anti-TNF therapy significantly reduced the levels of TNF and IL-18.28 Anti-IL-18 mAb was shown to result in a dramatic attenuation of TNBS colitis,29 and anti-TNF therapy was also shown HA130 to significantly reduce IL-18.28 Pentoxifylline showed therapeutic effects in human IBD and an experimental modal of colitis,30,31 by inhibiting the synthesis and IFN–inducing activity of IL-18.32 Moreover, anti-TNF therapy can decrease cell infiltration in the bowel after TNBS application by inducing apoptosis in lamina propria macrophages.28 In our previous study,3 we found that TNF- treated Caco2 and T84 monolayer cells.